InMed Pharmaceuticals Inc Stock price
Is InMed Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders or uses to reduce debt relative to its market capitalization. It goes beyond dividend yield by also including share buybacks and debt reduction.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. Companies can also return capital through share buybacks, while reducing debt can strengthen the balance sheet. Shareholder Yield combines all three components into one metric, giving investors a broader view of how a company uses its capital.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield generally indicates more capital being returned to shareholders or used to reduce debt.
- The mix matters: dividends, buybacks, and debt reduction can affect shareholders in different ways.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends, buybacks, and debt reduction are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
InMed Pharmaceuticals Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a InMed Pharmaceuticals Inc forecast:
Analyst Opinions
8 Analysts have issued a InMed Pharmaceuticals Inc forecast:
InMed Pharmaceuticals Inc Events
Past Events
|
MAY
19
InMed Pharmaceuticals Inc. - M&A Call
5 months ago
|
|
DEC
17
Shareholder/Analyst Call - InMed Pharmaceuticals Inc.
10 months ago
|
StocksGuide Free
InMed Pharmaceuticals Inc — InMed Pharmaceuticals Inc. - M&A Call
1. Management Discussion
Good morning, and welcome to today's conference call regarding the merger agreement between InMed Pharmaceuticals and Mentari Therapeutics. [Operator Instructions] Please be advised the call is being recorded and will be available for replay on the InMed website. Now I'd like to turn the call over to Colin Clancy, Vice President, Investor Relations and Corporate Communications, InMed Pharmaceuticals. Please proceed, sir.
Thank you, operator, and good morning, everyone. Before we continue, I would like to remind attendees that today's call may include forward-looking statements. These statements reflect the expectations and beliefs of both InMed Pharmaceuticals and Mentari Therapeutics regarding the potential outcomes of the merger and the future business plans. They may include projections on clinical development time lines, potential differentiation from other therapies, expected financial resources following the completion of the transaction, business milestones, market sizes and the potential benefit for shareholders. It is important to understand that these forward-looking statements are subject to risks and uncertainties. These risks include, but are not limited to, the ability to close the merger, achieve clinical milestones, maintain adequate funding and the conditions precedent to completion of the merger, including the receipt of required regulatory approvals and the ability to close the merger.
Our actual results may differ materially from expectations. For a discussion of risks and uncertainties, please review the descriptions included under the heading Risk Factors and Business in InMed's most recent annual report on Form 10-K filed with the SEC as well as other SEC filings made by InMed from time to time. In addition, InMed intends to file a proxy statement prospectus with the SEC in connection to the proposed merger, which will contain important information about Mentari, the combined company and additional risk factors related to the transaction.
Investors are urged to review the proxy statement prospectus carefully when it becomes available. These filings are available through the website maintained by the SEC at sec.gov and also available on InMed's website at inmedpharma.com. All forward-looking statements are made as of today's date. Except to the extent required by law, we do not undertake any obligation to update any forward-looking statements. We also caution you against placing undue reliance on any forward-looking statements. I will point out that our listeners can access additional information on Mentari in its corporate presentation, which is available on the Mentari website as well as on InMed in its corporate presentation, also available on its website.
Joining me on the call today are Eric Adams, President and CEO of InMed Pharmaceuticals, and Julianne Bruno, Chair of the Board of Mentari. We are thrilled to have this opportunity to tell you about Mentari Therapeutics and our plans to advance a pipeline of therapies intended to deliver freedom from the debilitating effects of migraine for millions of people worldwide.
Now I'd like to turn you over -- turn the call over to Eric Adams, President and CEO of InMed Pharmaceuticals.
Thank you, Colin. This morning, InMed issued a press release outlining a definitive merger agreement with Mentari Therapeutics as well as a private placement by a group of leading biotechnology investors supporting Mentari's pipeline programs, which is expected to close immediately prior to the completion of the merger.
This transaction represents a transformative event for InMed shareholders. For the last several years, in addition to our day-to-day drug development activities, we've been conducting a comprehensive review of strategic alternatives for InMed with the goal of maximizing long-term shareholder value. We have determined that a merger with Mentari represents the highest potential value creation opportunity for InMed shareholders. The merger between InMed and Mentari has been structured as an all-stock transaction. At close and at the expected deal price, the combined company's market capitalization is expected to be approximately $421 million. Under the terms of the merger agreement, premerger InMed shareholders are expected to own approximately 1.51% of the combined company. The percentage of the combined company that InMed shareholders will own as of the close of the transaction is, subject to adjustments based on the amount of InMed net cash at the closing date.
In addition to receiving a portion of the new combined company, InMed shareholders may continue to participate in the potential success of InMed's R&D programs, including INM-901 for Alzheimer's and INM-089 for age-related macular degeneration via a number of different financial mechanisms and instruments linked to a potential out-licensing or divestiture of these assets, if any. The mechanism and instruments include a potential dividend upon closing of the merger and contingent value rights entitling holders to a portion of the net proceeds, if any, received from any potential out-licensing or divestiture following the closing of the merger, again, if any.
These mechanisms and instruments are dependent on several unknown factors such as potential deal timing, potential deal proceeds and InMed's projected net cash position at the close of the merger. The merger is subject to approval by the shareholders of both companies as well as other customary closing conditions, including regulatory approvals. We expect the transaction to close in the second half of 2026. Upon completion, the combined company will operate under the name Mentari Therapeutics and trade on NASDAQ under the new ticker symbol. We believe this merger will enable Mentari to rapidly advance its migraine pipeline of potentially best-in-class therapies for migraine prevention, including its co-lead programs, MT-001 and MT-002, which you will hear more about in a moment.
It's now my pleasure to introduce Julianne Bruno, Chair of the Board for Mentari Therapeutics.
Thank you, Eric. We are thrilled to join forces with InMed to accelerate the development of potential therapies for people suffering from the debilitating effects of migraine. Mentari is the eighth company founded on assets licensed from Paragon Therapeutics, a leader in biologics discovery and protein engineering. Paragon has a strong track record of discovering and optimizing best-in-class biologics, including antibodies, bispecifics, ADCs and brain shuttles, enabling the development of potentially efficacious, safe therapies that maximize convenience for patients across a wide range of diseases.
Mentari was founded to rapidly advance potentially best-in-class therapies that provide freedom from migraine for millions of people and to provide a rapid value creation opportunity for investors. Migraine prevention has recently been enhanced by the development of CGRP-targeted therapies, which have revolutionized the migraine market. CGRP-targeted therapies are currently annualizing roughly $6 billion and are projected to grow to roughly $11 billion over the next several years. Despite these advances, significant unmet need remains for those who suffer from migraine as approximately 40% to 50% of patients treated with anti-CGRPs do not even achieve a 50% reduction in monthly migraine days and fewer than 1/3 of patients achieve a 75% reduction.
Mentari was created specifically to address these gaps. Mentari's pipeline has two parallel lead programs, MT-001 and MT-002. MT-001 is a potentially best-in-class anti-PACAP monoclonal antibody. PACAP is a newly validated target that acts via a pathway independent of CGRP, so it has potential to deliver efficacy for patients who do not respond to CGRPs. This potent half-life extended antibody was designed to deliver both high exposure against the target and convenient subcutaneous dosing. We expect to file a CTA or equivalent for MT-001 in mid-2026. With a clinical development plan built for expediency, we expect to deliver de-risking Phase I, [ PK ] and early safety data from healthy volunteers in 2027 with Phase IIa proof-of-concept data in chronic or episodic migraine coming in 2028.
MT-002 is an anti-CGRP and anti-PACAP bispecific antibody. By simultaneously blocking these complementary and validated targets, we believe MT-002 has potential to deliver greater efficacy for patients than either anti-CGRPs or anti-PACAP alone. MT-002 is also half-life extended, so it is expected to deliver high exposure against the targets with convenient subcutaneous dosing. We anticipate filing a CTA or equivalent for MT-002 in the first quarter of 2027, and we expect to deliver derisking Phase I PK and early safety data from healthy volunteers by year-end 2027.
Additional pipeline targets provide opportunities for novel combinations with our own potent half-life extended-CGRP antibody, MT-003, and two undisclosed targets, all in the migraine prevention space. Mentari's pipeline is supported by a strong financial foundation. Today, we announced commitments for an oversubscribed private investment that is expected to result in total gross proceeds of approximately $290 million. This private placement was led by Fairmount and joined by a syndicate of dedicated biotechnology investors.
As noted by Eric, the merger with InMed is expected to close in the second half of 2026. At that time and at the expected deal price, the combined company's market capitalization is expected to be approximately $421 million. The company's combined cash position at closing is expected to fund operations through 2028. Importantly, this runway is expected to fund the combined company beyond key value inflection points for both MT-001 and MT-002.
On behalf of the Mentari Therapeutics team, we are grateful to Eric, Colin and the whole team for their partnership, and we look forward to continued collaboration through the completion of the deal. Back to you, Eric.
Thank you, Julie. This merger marks an exciting moment for both InMed Pharmaceuticals and Mentari Therapeutics, and it positions Mentari to develop innovative therapies intended to provide freedom from the debilitating impacts of migraine. The merger and financing that we announced today are expected to provide resources for the advancement of Mentari's pipeline. With MT-001 and MT-002 on track for de-risking Phase I data in mid-2027 and by year-end 2027, respectively, Mentari is well positioned to deliver value to our investors following the merger and most importantly, potentially transformative medicines to patients. Thank you, everyone, for joining us this morning.
Ladies and gentlemen, this does conclude today's InMed Pharmaceuticals webcast. We thank you all for your participation. You may now disconnect your lines. Have a great day.
InMed Pharmaceuticals Inc — Shareholder/Analyst Call - InMed Pharmaceuticals Inc.
1. Management Discussion
Hello, and welcome to InMed Pharmaceuticals, Inc. 2025 Annual General Meeting of Shareholders. I will now turn the call over to Eric Adams, CEO. Please go ahead.
Thank you. Ladies and gentlemen, the annual general and special meeting of InMed Pharmaceuticals will now come to order. My name is Eric A. Adams. I'm the President, CEO and a Director of InMed Pharmaceuticals. I will act as Chair of this meeting. I ask that Sean Gillis of Norton Rose Fulbright Canada LLP and Legal Counsel to the company, act as Secretary of this meeting. And I appoint Jessica De La Torre of Odyssey Trust Company as scrutineer of this meeting.
The Secretary has tabled for inspection by any shareholder or proxyholder a sworn declaration that the notice calling this meeting and the accompanying materials, including the information circular were mailed to all security holders of record as of October 22, 2025. I will dispense with calling for a reading of the Notice of Meeting and direct that a copy of the declaration be kept by the secretary with the minutes of the meeting. The scrutineer has submitted a report on attendance to the Secretary. The Secretary will now read the scrutineer's report.
The scrutineer's report reads as follows. A quorum of shareholders is present for the transaction of business at this meeting if at least 2 persons are present in person and holding or representing, by proxy, not less than 33.3% of the shares entitled to vote at the meeting. I've been advised by the scrutineers that there are 43 shareholders present today, either in person or by proxy, representing 2,804,186 shares which is 35.43% of the issued and outstanding shares of InMed. Accordingly, we have quorum present.
I adopt the scrutineer's report and declare accordingly that a quorum is present. Adequate notice having been given and a quorum being present, I therefore declare this meeting to be properly constituted for the transaction of business.
Before continuing with the formal part of the meeting, I would like to note that present today and joining us by telephone are the directors, Andy Hull; Nicole Lemerond, John Bathery, Bryan Baldasare, and absent is Neil Klompas, who is traveling and unable to attend today.
As a matter of procedure, I ask that registered shareholders wishing to speak during the meeting, please identify themselves by name and indicate that they are registered shareholders or if a proxyholder, their name and the name of the registered shareholder they represent by proxy. I've been advised that we have guests at the meeting other than registered shareholders and proxyholders entitled to vote at this meeting. I welcome all guests. However, I would like to remind them that they do not have the legal right to vote on any resolution and are not entitled to speak at the meeting.
The financial statements of the company for the year ended June 30, 2025, and the report of the auditors thereon was delivered to the shareholders prior to this meeting. If there are any questions which any shareholder would like to ask in respect of the financial statements and the report, I'd be glad to answer them or call on others to do so. As there are no questions on this item, I declare that the audited financial statements for the year ended June 30, 2025, together with the auditor's report thereon have been received.
It is now in order to proceed with the nomination and election of directors. The number of directors of the company has been fixed at 5 and is anticipated that a full slate of directors will be elected. We have received no nominations for election as a director for the ensuing year from shareholders in accordance with the advance notice provisions contained in Section 14.2 of the company's articles or the Business Corporations Act of British Columbia. I now ask the Secretary to read the names of the persons nominated.
The names of the persons nominated for directors for the ensuing year are Ms. Nicole Lemerond, Mr. Andrew Hull, Mr. Eric A. Adams, Mr. Neil Klompas and Mr. John Bathery.
As the number of nominees is the same as the number of vacancies to be filled, I ask the secretary to read an individual motion for the election of each of the nominees as directors.
Be it resolved that Nicole Lemerond, be elected as a Director of the company to hold office until the next Annual General Meeting.
May I please have a motion and seconder for the election of Nicole Lemerond as a director.
So moved.
I second the motion.
I declare this resolution duly carried. I will now ask our Secretary to table our next individual resolution.
Be it resolved that Andrew Hull be elected as Director of the company to hold office until the next Annual General Meeting.
May I pleased to have a motion and a seconder for the election of Andrew Hull as a Director.
So moved.
I second the motion.
If there's no discussion, I declare this resolution duly carried. I will now ask our Secretary to table our next individual resolution.
Be it resolved that Eric Adams be elected as a Director of the company to hold office until the next Annual General Meeting.
May I please have a motion and seconder for the election of Eric Adams as a director.
So moved.
I second the motion.
If there's no discussion, I declare this resolution duly carried. I will now ask our Secretary to table our next individual resolution.
Be it resolved that Neil Klompas be elected as a Director of the company to hold office until the next Annual General Meeting.
May I please have a motion and a seconder for the election of Neil Klompas as a director.
So moved.
I second motion.
With no discussion on the matter, I declare this resolution duly carried. I will now ask our Secretary to table our next individual resolution.
Be it resolved that John Bathery be elected as a Director of the company to hold office until the next Annual General Meeting.
May I please have a motion and seconder for the election of John Bathery as a director.
So moved.
I second the motion.
I declare this resolution duly carried. The next item of business before the meeting relates to the appointment of the auditors of the company. I will now ask the Secretary to read the proposed motion.
Be it resolved that CBIZ CPAs P.C., be reappointed as auditors of the company to hold office until the next Annual General Meeting of the company and other directors of the company be authorized to fix the remuneration to be paid to the auditors.
May I please have a motion and seconder for the reappointment of CBIZ CPAs P.C. as auditor of the company.
So moved.
I second the motion.
If there's no discussion, I declare this motion duly carried. The next item of business before the meeting relates to the potential issuance of 20% or more of InMed Pharmaceuticals' issued and outstanding common shares as at December 13, 2024 pursuant to the standby equity purchase agreement between InMed Pharmaceuticals and YA II PN Limited dated December 13, 2024, as amended on June 13, 2025, pursuant to NASDAQ listing rules 5635(d) and 5635 (b).
I'll refer to this business as CPA share issuance. Approval of the CPA share issuance will allow the company to issue common shares under the standby equity purchase agreement in excess of the current maximum being 144,758 common shares, representing 19.99% of the issued and outstanding common shares of the company immediately prior to December 13, 2024, being end to date of execution of the standby equity purchase agreement at a share price below the minimum price under the standby equity purchase agreement of $5.15 per common share. I now ask the Secretary to read the proposed motion.
Be it resolved that the company may issue 20% or more of InMed Pharmaceuticals issued and outstanding common shares as of December 13, 2024, pursuant to the standby equity purchase agreement between InMed Pharmaceuticals and YA II PN Limited dated December 13, 2024, as amended on June 13, 2025 at a price per common share of less than $5.15.
May I please have a motion and a seconder for the CPA share issuance resolution.
So moved.
I second the motion.
If there's no discussion, this motion is carried. Is there any other further business to be brought before the meeting? Okay. I now propose a motion terminating the meeting. May I please have a motion and seconder for the termination of the meeting.
So moved.
I second the motion.
If there's no discussion, I declare this resolution duly carried and the meeting to be terminated. Before I pass this back over to the operator, I just want to take a moment to thank one individual who's contributed several years to the Board of Directors, Mr. Bryan Baldasare, who has elected to step down from the Board due to his personal increasing professional commitments. I just hope that in the future, Bryan finds time to help other companies like ours. He's done an incredible job with us. And I think other companies could benefit from his experience, his expertise and his perspective. So Bryan, thank you very much, and good luck to you.
With that, I'll turn it back over to the operator.
Ladies and gentlemen, this concludes today's call. Thank you all for joining, and you may now disconnect.
Financial data from InMed Pharmaceuticals Inc
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Mar '26 |
+/-
%
|
||
| Revenue | 3.25 3.25 |
11%
11%
100%
|
|
| - Direct Costs | - - |
-
-
|
|
| Gross Profit | - - |
-
-
|
|
| - Selling and Administrative Expenses | 7.14 7.14 |
24%
24%
220%
|
|
| - Research and Development Expense | 2.36 2.36 |
30%
30%
73%
|
|
| EBITDA | -8.33 -8.33 |
8%
8%
-256%
|
|
| - Depreciation and Amortization | 0.21 0.21 |
34%
34%
6%
|
|
| EBIT (Operating Income) EBIT | -8.54 -8.54 |
6%
6%
-263%
|
|
| Net Profit | -8.51 -8.51 |
2%
2%
-262%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about InMed Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InMed Pharmaceuticals Inc Stock News
Company Profile
InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
StocksGuide Premium
| Head office | Canada |
| CEO | Mr. Adams |
| Employees | 13 |
| Founded | 1981 |
| Website | www.inmedpharma.com |
